Evidence map›Paper›PMID 33404923›Full record

ArticleCardiovascular drugs and therapy2021

Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation.

Alexandros Briasoulis, Amgad Mentias, Alexander Mazur, Paulino Alvarez, Enrique C Leira, Mary S Vaughan Sarrazin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 5 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022
    Review
  16. Article
  17. Article
  18. Article
  19. Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021.European heart journal. Cardiovascular pharmacotherapy · 2021
    Article
  20. Letter to the editor in response to Komen et al. 2021.European heart journal. Cardiovascular pharmacotherapy · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Alexandros BriasoulisDivision of Cardiovascular Diseases, Department of Internal Medicine, University of Iowa College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA. alexbriasoulis@gmail.com.ORCID 0000-0002-5740-9670
Amgad MentiasDivision of Cardiovascular Diseases, Department of Internal Medicine, University of Iowa College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Alexander MazurDivision of Cardiovascular Diseases, Department of Internal Medicine, University of Iowa College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Paulino AlvarezDivision of Cardiovascular Diseases, Department of Internal Medicine, University of Iowa College of Medicine, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Enrique C LeiraDepartments of Neurology and Neurosurgery, Carver College of Medicine, and Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA.
Mary S Vaughan SarrazinDivision of General Medicine, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA, USA.
University of Iowa · US

Funding

Dosing of Direct Oral Anticoagulants for stroke prevention in Atrial Fibrillation: Patterns, Consequences, and GuidanceR01AG055663 · NIA · UNIVERSITY OF IOWA · PI VAUGHAN SARRAZIN, MARY S · 2017 to 2019
$844k
NIA NIH HHS R01 AG055663
6 · The paper itself

Abstract

backgroundUnlike warfarin direct oral anticoagulants (DOACs) are administered in fixed doses, which raises concerns of its effectiveness on larger patients. Data from randomized trials are limited on the safety and efficacy of DOACs in morbidly obese individuals with atrial fibrillation (AF).

methodsWe analyzed a cohort of obese (≥ 120 kg) and morbidly obese (BMI > 40 kg/m

resultsWe identified 6052 obese patients on apixaban, 4233 on dabigatran, 4309 on rivaroxaban, and 13,417 on warfarin (mean age 66.7 years, 91% males, 80.4% whites). At baseline patients on apixaban had the lowest glomerular filtration rate and highest rates of previous stroke and MI compared to other OACs. Among patients with weight ≥ 120 kg and those with BMI > 40 kg/m

conclusionsIn this large cohort of obese Veterans Health Administration system patients, the use of DOACs resulted in lower hemorrhagic complications than warfarin while maintaining efficacy on ischemic stroke prevention.

Indexed as

Administration, OralAgedAnticoagulantsAtrial FibrillationBacterial ProteinsCardiovascular DiseasesFactor Xa InhibitorsFemaleGlomerular Filtration RateHemorrhageHumansMaleMiddle AgedObesityObesity, MorbidProportional Hazards ModelsAnticoagulantsBacterial ProteinsComS protein, Bacillus subtilisFactor Xa InhibitorsAtrial fibrillationBleedingDirect oral anticoagulantsObesityStroke

Identifiers

PMID33404923
PMCPMC8382577
OpenAlexW3119380819

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.